✦ LIBER ✦

9141 POSTER Phase l/ll Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression – the TARZO Trial (NCT00503971)

✍ Scribed by Cardenal, F.; Reguart, N.; Morán, T.; Insa, A.; Isla, L.; Magern, M.; Rolfo, C.; De Castro, J.; Queralt, C.; Rosell, R.

Book ID: 122399497
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 61 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)72453-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9150 Phase I trial of vorinostat in comb

9150 Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial

✍ Reguart, N.; Isla, D.; Cardona, A.F.; Palmero, R.; Cardenal, F.; Rolfo, C.; Mont 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Phase I/II trial of vorinostat (SAHA) an

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

✍ Reguart, Noemi; Rosell, Rafael; Cardenal, Felipe; Cardona, Andres F.; Isla, Dolo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 645 KB

Randomized Phase II Trial of Onartuzumab

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Ervin, T. J.; Ramlau, R. A.; Daniel, D. B.; Goldschmidt, J. H.; B 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 266 KB

9016 POSTER DISCUSSION Erlotinib Vs Chem

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results

✍ De Marinis, F.; Rosell, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Gervais, R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

9035 POSTER A National, Multi Center, Ra

9035 POSTER A National, Multi Center, Randomized, Open-label, Phase II Study of Erlotinib Versus Gemcitabine (GEM) Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer (NSCLC) Patients (pts) With Activating EGFR Mutations (C-TONG 1103)

✍ Zhonq, W.; Wu, Y.; Wang, C.; Mao, W.; Xu, L.; Cheng, Y.; Yang, X.; Chen, K. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB